Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $34.50 for the company, according to Zacks. Zacks has also given Kala Pharmaceuticals an industry rank of 105 out of 265 based on the ratings given to related companies.

A number of brokerages have recently issued reports on KALA. Bank of America Corporation began coverage on shares of Kala Pharmaceuticals in a research report on Monday, August 14th. They set a “buy” rating and a $33.00 price objective for the company. Wedbush began coverage on shares of Kala Pharmaceuticals in a research report on Monday, August 14th. They set an “outperform” rating and a $46.00 price objective for the company. J P Morgan Chase & Co began coverage on shares of Kala Pharmaceuticals in a research report on Monday, August 14th. They set an “overweight” rating and a $35.00 price objective for the company. Wells Fargo & Company began coverage on shares of Kala Pharmaceuticals in a research report on Monday, August 14th. They set an “outperform” rating and a $24.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. began coverage on shares of Kala Pharmaceuticals in a research report on Tuesday, August 15th. They set an “outperform” rating and a $46.00 price objective for the company.

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/kala-pharmaceuticals-inc-kala-given-consensus-rating-of-strong-buy-by-brokerages.html.

In other news, Director Rajeev M. Shah bought 533,333 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was bought at an average price of $15.00 per share, with a total value of $7,999,995.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Orbimed Advisors Llc bought 319,333 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average cost of $15.00 per share, with a total value of $4,789,995.00. The disclosure for this purchase can be found here. Insiders purchased a total of 1,282,666 shares of company stock valued at $19,239,990 in the last ninety days.

Kala Pharmaceuticals (KALA) traded down 1.12% during midday trading on Wednesday, hitting $22.91. The company’s stock had a trading volume of 82,632 shares. The firm’s market cap is $555.04 million. The company’s 50 day moving average price is $23.19 and its 200 day moving average price is $21.08. Kala Pharmaceuticals has a 12 month low of $16.38 and a 12 month high of $26.75.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.